Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
Mol Cancer Ther. 2013 Sep;12(9):1749-62. doi: 10.1158/1535-7163.MCT-13-0075. Epub 2013 Jun 26.
Mol Cancer Ther. 2013.
PMID: 23804704
The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy.
Clémenson C, Chargari C, Liu W, Mondini M, Ferté C, Burbridge MF, Cattan V, Jacquet-Bescond A, Deutsch E.
Clémenson C, et al. Among authors: jacquet bescond a.
Mol Cancer Ther. 2017 Oct;16(10):2107-2119. doi: 10.1158/1535-7163.MCT-17-0112. Epub 2017 Jun 15.
Mol Cancer Ther. 2017.
PMID: 28619752
Item in Clipboard
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
Guffanti F, Chilà R, Bello E, Zucchetti M, Zangarini M, Ceriani L, Ferrari M, Lupi M, Jacquet-Bescond A, Burbridge MF, Pierrat MJ, Damia G.
Guffanti F, et al. Among authors: jacquet bescond a.
Neoplasia. 2017 Jan;19(1):35-42. doi: 10.1016/j.neo.2016.11.008. Epub 2016 Dec 15.
Neoplasia. 2017.
PMID: 27988457
Free PMC article.
Item in Clipboard
Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I.
Fouliard S, Robert R, Jacquet-Bescond A, du Rieu QC, Balasubramanian S, Loury D, Loriot Y, Hollebecque A, Kloos I, Soria JC, Chenel M, Depil S.
Fouliard S, et al. Among authors: jacquet bescond a.
Eur J Cancer. 2013 Sep;49(13):2791-7. doi: 10.1016/j.ejca.2013.05.009. Epub 2013 Jun 18.
Eur J Cancer. 2013.
PMID: 23790467
Clinical Trial.
Item in Clipboard
Treatment of nasopharyngeal carcinoma cells with the histone-deacetylase inhibitor abexinostat: cooperative effects with cis-platin and radiotherapy on patient-derived xenografts.
Gressette M, Vérillaud B, Jimenez-Pailhès AS, Lelièvre H, Lo KW, Ferrand FR, Gattolliat CH, Jacquet-Bescond A, Kraus-Berthier L, Depil S, Busson P.
Gressette M, et al. Among authors: jacquet bescond a.
PLoS One. 2014 Mar 11;9(3):e91325. doi: 10.1371/journal.pone.0091325. eCollection 2014.
PLoS One. 2014.
PMID: 24618637
Free PMC article.
Item in Clipboard
Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor.
Chalret du Rieu Q, Fouliard S, Jacquet-Bescond A, Robert R, Kloos I, Depil S, Chatelut E, Chenel M.
Chalret du Rieu Q, et al. Among authors: jacquet bescond a.
Pharm Res. 2013 Oct;30(10):2640-53. doi: 10.1007/s11095-013-1089-1. Epub 2013 Jun 5.
Pharm Res. 2013.
PMID: 23737346
Item in Clipboard
Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms.
Ali A, Bluteau O, Messaoudi K, Palazzo A, Boukour S, Lordier L, Lecluse Y, Rameau P, Kraus-Berthier L, Jacquet-Bescond A, Lelièvre H, Depil S, Dessen P, Solary E, Raslova H, Vainchenker W, Plo I, Debili N.
Ali A, et al. Among authors: jacquet bescond a.
Cell Death Dis. 2013 Jul 25;4(7):e738. doi: 10.1038/cddis.2013.260.
Cell Death Dis. 2013.
PMID: 23887629
Free PMC article.
Item in Clipboard
Cite
Cite